X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs DR. REDDYS LAB - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES DR. REDDYS LAB PIRAMAL ENTERPRISES/
DR. REDDYS LAB
 
P/E (TTM) x 10.9 32.0 34.2% View Chart
P/BV x 1.9 3.4 54.9% View Chart
Dividend Yield % 0.9 0.8 112.7%  

Financials

 PIRAMAL ENTERPRISES   DR. REDDYS LAB
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-18
DR. REDDYS LAB
Mar-18
PIRAMAL ENTERPRISES/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs3,0832,788 110.6%   
Low Rs1,9021,902 100.0%   
Sales per share (Unadj.) Rs589.7860.8 68.5%  
Earnings per share (Unadj.) Rs284.057.1 497.7%  
Cash flow per share (Unadj.) Rs310.5122.0 254.5%  
Dividends per share (Unadj.) Rs25.0020.00 125.0%  
Dividend yield (eoy) %1.00.9 117.6%  
Book value per share (Unadj.) Rs1,467.0757.7 193.6%  
Shares outstanding (eoy) m180.27165.91 108.7%   
Bonus/Rights/Conversions ISESOP-  
Price / Sales ratio x4.22.7 155.2%   
Avg P/E ratio x8.841.1 21.4%  
P/CF ratio (eoy) x8.019.2 41.8%  
Price / Book Value ratio x1.73.1 54.9%  
Dividend payout %8.835.0 25.1%   
Avg Mkt Cap Rs m449,332389,034 115.5%   
No. of employees `0006.823.5 29.1%   
Total wages/salary Rs m19,88132,149 61.8%   
Avg. sales/employee Rs Th15,535.66,070.8 255.9%   
Avg. wages/employee Rs Th2,905.41,366.6 212.6%   
Avg. net profit/employee Rs Th7,482.5402.5 1,859.1%   
INCOME DATA
Net Sales Rs m106,310142,810 74.4%  
Other income Rs m2,5951,552 167.2%   
Total revenues Rs m108,906144,362 75.4%   
Gross profit Rs m51,59923,512 219.5%  
Depreciation Rs m4,77310,772 44.3%   
Interest Rs m29,783788 3,779.6%   
Profit before tax Rs m19,63813,504 145.4%   
Minority Interest Rs m2,8010-   
Prior Period Items Rs m0344 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-28,7644,380 -656.7%   
Profit after tax Rs m51,2039,468 540.8%  
Gross profit margin %48.516.5 294.8%  
Effective tax rate %-146.532.4 -451.6%   
Net profit margin %48.26.6 726.5%  
BALANCE SHEET DATA
Current assets Rs m118,154104,984 112.5%   
Current liabilities Rs m462,26068,938 670.5%   
Net working cap to sales %-323.725.2 -1,282.4%  
Current ratio x0.31.5 16.8%  
Inventory Days Days2774 35.7%  
Debtors Days Days47104 44.9%  
Net fixed assets Rs m113,727104,385 108.9%   
Share capital Rs m361830 43.4%   
"Free" reserves Rs m264,093124,886 211.5%   
Net worth Rs m264,454125,716 210.4%   
Long term debt Rs m242,20625,089 965.4%   
Total assets Rs m726,834225,443 322.4%  
Interest coverage x1.718.1 9.1%   
Debt to equity ratio x0.90.2 458.9%  
Sales to assets ratio x0.10.6 23.1%   
Return on assets %11.14.5 244.9%  
Return on equity %19.47.5 257.1%  
Return on capital %10.39.7 106.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,11072,623 20.8%   
Fx outflow Rs m4,29818,916 22.7%   
Net fx Rs m10,81353,707 20.1%   
CASH FLOW
From Operations Rs m-159,66618,030 -885.6%  
From Investments Rs m-17,677-14,883 118.8%  
From Financial Activity Rs m186,503-4,440 -4,200.5%  
Net Cashflow Rs m9,364-1,236 -757.6%  

Share Holding

Indian Promoters % 52.9 25.5 207.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 5.4 74.1%  
FIIs % 26.6 35.3 75.4%  
ADR/GDR % 0.0 18.5 -  
Free float % 16.5 15.3 107.8%  
Shareholders   93,274 75,885 122.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   J.B.CHEMICALS  SUVEN LIFE  STERLING BIOTECH  CADILA HEALTHCARE  VENUS REMEDIES  

Compare PIRAMAL ENTERPRISES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY19); Net Profit Down 152.5% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 1 bn (down 152.5% YoY). Sales on the other hand came in at Rs 29 bn (up 28.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Sep 19, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS